Veerhealth Care Limited has announced a board meeting to deliberate on fund raising proposals, marking a significant corporate development for the Mumbai-based company. The announcement was made through an official regulatory filing under Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to regulatory compliance and transparent stakeholder communication.

Board Meeting Details

The board meeting has been scheduled with specific parameters as outlined in the company's regulatory filing dated March 20, 2026:

Fund Raising Proposal Overview

The board will consider and approve proposals for raising funds through multiple financial instruments. The company has outlined several potential funding mechanisms to provide flexibility in its capital raising strategy:

• Equity shares issuance
• Convertible securities
• Preferential Issue
• Rights Issue
• Qualified Institutional Placement (QIP)
• Other modes as deemed appropriate

All proposed funding methods will be subject to necessary regulatory approvals and compliance requirements as mandated under applicable securities regulations.

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct for Prevention of Insider Trading, Veerhealth Care Limited has implemented a trading window closure. The restriction affects designated persons and their relatives, preventing them from dealing in the company's securities from the date of intimation until 48 hours after the board meeting concludes.

Shareholder Approval Process

The board will also deliberate on convening an Extraordinary General Meeting or initiating a Postal Ballot process to obtain shareholder approval for the proposed fund raising initiative. This step ensures compliance with regulatory requirements and maintains transparency in corporate governance practices.

Company Information

Veerhealth Care Limited operates under CIN L65910MH1992PLC067632 and trades on BSE under the code 511523. The regulatory filing was signed by Managing Director Bhavin S. Shah (DIN: 03129574), reflecting the company's adherence to proper corporate governance and regulatory disclosure norms.

Veerhealth Care Ltd. has announced securing its largest order worth ₹5.49 crores from one of India's leading Fast Moving Consumer Goods (FMCG) companies for personal care products. The order, valued at approximately ₹5.50 crores excluding GST, represents a substantial milestone for the company and provides significant revenue visibility for the current financial year.

Order Significance and Financial Impact

The contract demonstrates remarkable scale relative to the company's current operations. With Q3 FY26 revenue from operations at ₹7.26 crores, this single order represents approximately 76% of the quarterly revenue. More significantly, the order alone constitutes about 20% of the company's expected revenues for FY 2025-26.

Order Details and Client Profile

The contract involves supplying face care products to a prominent domestic FMCG company that operates in both domestic and international markets within the personal and household care segment. The client is part of a 125-year-old established business group, adding credibility to the partnership. While the client's identity remains confidential due to contractual terms, the order must be executed within a tight 45-day timeline.

Future Revenue Projections and Growth Strategy

Management has provided ambitious growth projections for the coming years. For FY 2026-27, the company expects total revenues of ₹45-50 crores with a profit after tax (PAT) margin of 7-10%. However, considering ongoing discussions for orders from both domestic and export buyers, the company anticipates potentially exceeding these revenue targets.

Competitive Positioning and Manufacturing Capabilities

Veerhealth Care has established a distinctive market position through its USFDA plant clearance, a certification achieved by very few small-cap companies globally. The company specializes in manufacturing pure vegetarian toothpaste and operates under the Ayuveer brand, which focuses on crafting ayurvedic medicines and oral care products using natural ingredients. This combination of regulatory approval and specialized manufacturing capabilities positions the company favorably for future growth in the personal care segment.

Regulatory Compliance and Corporate Governance

The announcement was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that no promoter, promoter group, or group companies have any interest in the entity that awarded the order, ensuring the transaction maintains high corporate governance standards and does not constitute a related party transaction.